Abstract 2046
Background
There is no standard third-line chemotherapy after progression on two-lines of therapy including gemcitabine/platinum and FOLFOX-4 based chemotherapy regimens in metastatic gall bladder cancer patients. So this study was undertaken to assess the efficacy and safety of single agent nab-paclitaxel in this setting.
Methods
The was a single arm prospective study, patients with performance status ≤2, who progressed on two-lines of therapy, were enrolled from May 2012 to December 2015. Single agent nab-paclitaxel (dose 125mg/m2) was administered on Day 1, 8 and 15 in a cycle of 28 days and i.e. until progression or unacceptable toxicity. Response evaluation was done after 2 cycles of chemotherapy.
Results
A total of 24 patients were enrolled in this study. The median age of patients was 60 years (31–71 years), of which 10 (41.66%) were males and 14 (58.33%) were females. The median number of cycles could be given were 3.07 (0.5 – 9.6). 13 patients (54.16%) could be given more than 3 cycles of chemotherapy and only 3 patients (12.5%) in this study received more than 6 cycles of chemotherapy. Disease control rate was seen in 16 (66.66%) patients, with complete response in none, partial response in 9 (37.5%), stable disease in 7 (29.16%) and progressive disease in 8 (33.33%) patients. The median progression free survival was 2.86 months (95% CI: 2.31-3.41); The main Grade 3/4 side effects seen were hematological in 33.33% (n = 8). 7 patients (29.16%) had Grade 1/2 peripheral neuropathy.
Conclusions
Nab-paclitaxel is an effective and well-tolerated agent as a third-line option in metastatic gall bladder cancer patients. Further studies are required, especially in the Indian subcontinent.
Clinical trial identification
None
Legal entity responsible for the study
Rajiv Gandhi Cancer Institute
Funding
Rajiv Gandhi Cancer Institute
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
ZUMA-3: A phase 1/2 multi-center study evaluation the safety and efficacy of KTE-C19 anti-CD19 CAR T cells in adult patients with relapsed/refractory B precursor acute lymphoblastic leukemia (R/R ALL)
Presenter: Bijal Shah
Session: Poster display
Resources:
Abstract
ZUMA-2: A phase 2 multi-center study evaluating the efficacy of KTE-C19 (Anti-CD19 CAR T cells) in patients with relapsed/refractory Mantle cell lymphoma (R/R MCL)
Presenter: Michael Wang
Session: Poster Display
Resources:
Abstract
ZUMA-1: A phase 2 multi-center study evaluating anti-CD19 chimeric antigen receptor (CAR) T cells in patients with refractory aggressive non-Hodgkin lymphoma (NHL)
Presenter: Sattva Neelapu
Session: Poster Display
Resources:
Abstract
Younger age as a prognostic indicator in breast cancer: Correlation between clinical-pathologic factors and miRNAs and long-term follow-up
Presenter: Maria Teresa Martinez
Session: Poster display
Resources:
Abstract
Window study of the PARP inhibitor rucaparib in patients with primary triple negative or BRCA1/2 related breast cancer (RIO)
Presenter: Christy Toms
Session: Poster display
Resources:
Abstract
Whole exome sequencing (WES) and RNA sequencing (RNA-seq) in routine clinical practice for colorectal cancer (CRC) and non-small cell lung cancer (NSCLC) patients (pts)
Presenter: Géraldine Perkins
Session: Poster display
Resources:
Abstract
What is the optimal annual interpretive volume for a radiologist reading screening mammograms?
Presenter: Asli Uluturk
Session: Poster display
Resources:
Abstract
What decides breast conservation versus mastectomy in the background of diverse sociocultural environment, an Indian study
Presenter: Poonamalle Padmanabhan Bapsy
Session: Poster display
Resources:
Abstract
Waiting time to diagnosis and treatment of the head and neck cancer in four institutions in Portugal
Presenter: Ana Castro
Session: Poster display
Resources:
Abstract
Wait times for diagnosis and treatment of lung cancer: a single centre experience
Presenter: Catherine Labbe
Session: Poster Display
Resources:
Abstract